Kwon, Soonil
Choi, Eue-Keun
Ahn, Hyo-Jeong
Lee, So-Ryoung
Oh, Seil
Kim, Si Hyun
Do, Minh-Tung
Han, Jang Hee
Jeong, Chang Wook
Funding for this research was provided by:
National Research Foundation of Korea (2020R1F1A106740)
DeepQure, Inc, Seoul, Republic ok Korea (0620221670)
Article History
Received: 5 June 2023
Accepted: 8 November 2023
First Online: 11 November 2023
Competing interests
: EKC: Research grants or speaking fees from Abbott, Bayer, BMS/Pfizer, Biosense Webster, Chong Kun Dang, Daewoong Pharmaceutical Co., Daiichi-Sankyo, DeepQure, Dreamtech Co., Ltd., Jeil Pharmaceutical Co. Ltd, Medtronic, Samjinpharm, Seers Technology, and Skylabs. Stock options from Seers Technology, and Skylabs. Stock from DeepQure. CWJ: Co-founder, major shareholder, and Director (Chief medical officer) of DeepQure Inc. Research fund from DeepQure, Inc. The inventor of the HyperQureâ„¢ RDN system. The other authors have nothing to disclose.